Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salmeterol/fluticasone MDI HEXAL versus Seretide Evohaler in moderate-to-severe persistent asthma
2007-005235-29Phase 3Completed
- Sponsor
- Hexal AG
- Start
- Jan 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of salmeterol + fluticasone in asthma and persistent asthma (2 arms), sponsored by Hexal AG. Primary endpoints: Change in FEV1 at week 12 versus baseline and Area under the 12-hour serial FEV1 curve (AUC0-12) at end of treatment relative to baseline. Started Jan 2008; status: completed.
02
Drugs
salmeterol + fluticasone
03
Conditions
asthmapersistent asthma
Beyond the preview
Go deeper on 2007-005235-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005235-29.